Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade

References

• Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018. DOI:10.1136/bmj.k793.
   Google Scholar
• Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2017. DOI:10.1136/annrheumdis-2017-212257.
   Google Scholar
• Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017. DOI:10.1200/JCO.2015.66.1389.
   Google Scholar
• Solinas C, Porcu M, De Silva P, et al. Cancer immunotherapy-associated hypophysitis. Semin Oncol. 2018;45:181–186.
   Google Scholar
• Porcu M, De Silva P, Solinas C, et al. Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological features. Cancers (Basel). 2019. DOI:10.3390/cancers11030305.
   Google Scholar
• Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709–717.
   Google Scholar
• Andruska N, Mahapatra L, Hebbard C, et al. Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy. BMJ Case Rep. 2018;bcr-2018-225937. DOI:10.1136/bcr-2018-225937.
   Google Scholar
• Immune related adverse events (irAE) | BSMO. n.d. [cited 2019 May 21]. Available from: https://www.bsmo.be/immunomanager/irae/
   Google Scholar
• Suresh K, Naidoo J, Lin CT, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest. 2018;154:1416–1423.
   Google Scholar
• Cui P, Liu Z, Wang G, et al. Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study. Cancer Med. 2018;7:4115–4120.
   Google Scholar
• Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22:6051–6060.
   Google Scholar
• Pradère P, Boutros C, Scoazec JY, et al. Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors? Eur J Cancer. 2018;93:144–146.
   Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168.
   Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–1755.
   Google Scholar
• Läubli H, Koelzer VH, Matter MS, et al. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology. 2018;7:e1386362.
   Google Scholar
• Tanaka K, Yanagihara T, Ikematsu Y, et al. Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Oncotarget. 2018;9. DOI:10.18632/oncotarget.25743.
   Google Scholar
• Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7. DOI:10.1038/ncomms10391.
   Google Scholar
• Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010;107:12204–12209.
   Google Scholar
• Faith JJ, Ahern PP, Ridaura VK, et al. Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice. Sci Transl Med. 2014;6:220ra11-220ra11.
   Google Scholar
• Das R, Bar N, Ferreira M, et al. Early b cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128:715–720.
   Google Scholar
• Valpione S, Pasquali S, Campana LG, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med. 2018;16. DOI:10.1186/s12967-018-1467-x.
   Google Scholar
• Desai MK, Brinton RD. Autoimmune disease in women: endocrine transition and risk across the lifespan. Front Endocrinol (Lausanne). 2019;10. DOI:10.3389/fendo.2019.00265.
   Google Scholar
• Martins F, Sykiotis GP, Maillard M, et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019;20:e54-e64.
   Google Scholar
• Wang DY, Salem J-E, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncol. 2018;4:1721.
   Google Scholar
• Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50. DOI:10.1183/13993003.00050-2017.
   Google Scholar
• Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018. DOI:10.1016/j.lungcan.2017.11.019.
   Google Scholar
• Kim HI, Kim M, Lee SH, et al. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology. 2017;7:1–6.
   Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016;387:1540–1550.
   Google Scholar
• Robert C, Ribas A, Hamid O, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36:1668–1674.
   Google Scholar
• Myint Zin, Ruta Arays Arun K.Raajasekar Arumugam, et al. Long-term outcomes in patients after discontinuation of immune checkpoint inhibitors. J Clin Res Med. 2018;1(3):1–4.
   Google Scholar
• Gauci ML, Lanoy E, Champiat S, et al. Long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin Cancer Res. 2019;25:946–956.
   Google Scholar
• Weiss SA, Wolchok JD, Sznol M. Immunotherapy of melanoma: facts and hopes. Clin Cancer Res. 2019;25:5191–5201.
   Google Scholar